Table 1. Patient and transplant... | American Society of Hematology

Table 1.

Patient and transplant characteristics

			Regimen
Characteristic	Entire cohort	%*	BuFlu±TT	%	TreoFlu±TT	%	P
Patients	197	100	103	52.3	94	47.7	NA
Follow-up, median (IQR), mo	44.9 (25.5-70.4)	NA	44.8 (24.0-60.2)	NA	46.4 (26.0-80.1)	NA	NA
Age at HSCT, median (IQR), y	1.6 (1.0-3.1)	NA	1.6 (0.9-3.9)	NA	1.6 (1.1-2.5)	NA	.833†
<5 y	165	83.8	84	81.6	81	86.2	.404
≥5 to <18 y	24	12.2	13	12.6	11	11.7
≥18 y	8	4.1	6	5.8	2	2.1
WAS score at HSCT‡
1-2	24	17.8	6	8.7	18	27.3	.011
3-4	71	52.6	43	62.3	28	42.4
5	40	29.6	20	29.0	20	30.3
Missing	62
Pre-HSCT autoimmunity
Yes	61	38.9	31	36.9	30	41.1	.625
No	96	61.1	53	63.1	43	58.9
Missing	40
Conditioning regimen
No thiotepa	155	78.7	86	83.5	69	73.4	.12
Thiotepa	42	21.3	17	16.5	25	26.6
Serotherapy
Yes	161	81.7	77	74.8	84	89.4	.014
Antithymocyte globulin Alemtuzumab	96 65	48.7 33.0	53 24	51.5 23.3	43 41	45.7 43.6
No	36	18.3	26	25.2	10	10.6
Donor
MSD/MFD	39	20.0	26	25.5	13	14.0	.093
10/10 MUD	86	44.1	39	38.2	47	50.5
9/10 MUD	28	14.4	15	14.7	13	14
<9/10 MMUD	14	7.2	10	9.8	4	4.3
MMFD§	28	14.4	12	11.8	16	17.2
Missing	2
Stem cell source
Bone marrow	103	52.6	61	59.2	42	45.2	.031
Peripheral blood	72	36.7	29	28.2	43	46.2
Cord blood	21	10.7	13	12.6	8	8.6
Missing	1
Cytomegalovirus(recipient/donor)
–/–	49	26.8	20	20.8	29	33.3	.244
–/+	26	14.2	16	16.7	10	11.5
+/–	29	15.8	15	15.6	14	16.1
+/+	79	43.2	45	46.9	34	39.1
Missing	14
Period of HSCT
2014-2017	86	43.7	55	53.4	31	32.9	.006
2006-2013	111	56.3	48	46.6	63	67.1
Graft manipulation
No	149	76.0	79	76.7	70	75.3	.947
Yes	47	24.0	24	23.3	23	24.7
Missing	1
GVHD prophylaxis
CNI/mycophenolate mofetil	87	44.2	37	35.9	50	53.2	.087
CNI/methotrexate	52	26.4	33	32.0	19	20.2
Other	45	22.8	25	24.3	20	21.3
None	13	6.6	8	7.8	5	5.3

			Regimen
Characteristic	Entire cohort	%*	BuFlu±TT	%	TreoFlu±TT	%	P
Patients	197	100	103	52.3	94	47.7	NA
Follow-up, median (IQR), mo	44.9 (25.5-70.4)	NA	44.8 (24.0-60.2)	NA	46.4 (26.0-80.1)	NA	NA
Age at HSCT, median (IQR), y	1.6 (1.0-3.1)	NA	1.6 (0.9-3.9)	NA	1.6 (1.1-2.5)	NA	.833†
<5 y	165	83.8	84	81.6	81	86.2	.404
≥5 to <18 y	24	12.2	13	12.6	11	11.7
≥18 y	8	4.1	6	5.8	2	2.1
WAS score at HSCT‡
1-2	24	17.8	6	8.7	18	27.3	.011
3-4	71	52.6	43	62.3	28	42.4
5	40	29.6	20	29.0	20	30.3
Missing	62
Pre-HSCT autoimmunity
Yes	61	38.9	31	36.9	30	41.1	.625
No	96	61.1	53	63.1	43	58.9
Missing	40
Conditioning regimen
No thiotepa	155	78.7	86	83.5	69	73.4	.12
Thiotepa	42	21.3	17	16.5	25	26.6
Serotherapy
Yes	161	81.7	77	74.8	84	89.4	.014
Antithymocyte globulin Alemtuzumab	96 65	48.7 33.0	53 24	51.5 23.3	43 41	45.7 43.6
No	36	18.3	26	25.2	10	10.6
Donor
MSD/MFD	39	20.0	26	25.5	13	14.0	.093
10/10 MUD	86	44.1	39	38.2	47	50.5
9/10 MUD	28	14.4	15	14.7	13	14
<9/10 MMUD	14	7.2	10	9.8	4	4.3
MMFD§	28	14.4	12	11.8	16	17.2
Missing	2
Stem cell source
Bone marrow	103	52.6	61	59.2	42	45.2	.031
Peripheral blood	72	36.7	29	28.2	43	46.2
Cord blood	21	10.7	13	12.6	8	8.6
Missing	1
Cytomegalovirus(recipient/donor)
–/–	49	26.8	20	20.8	29	33.3	.244
–/+	26	14.2	16	16.7	10	11.5
+/–	29	15.8	15	15.6	14	16.1
+/+	79	43.2	45	46.9	34	39.1
Missing	14
Period of HSCT
2014-2017	86	43.7	55	53.4	31	32.9	.006
2006-2013	111	56.3	48	46.6	63	67.1
Graft manipulation
No	149	76.0	79	76.7	70	75.3	.947
Yes	47	24.0	24	23.3	23	24.7
Missing	1
GVHD prophylaxis
CNI/mycophenolate mofetil	87	44.2	37	35.9	50	53.2	.087
CNI/methotrexate	52	26.4	33	32.0	19	20.2
Other	45	22.8	25	24.3	20	21.3
None	13	6.6	8	7.8	5	5.3

CNI, calcineurin inhibitor (cyclosporin A or tacrolimus); IQR, interquartile range; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; NA, not applicable.

Percentages are calculated within the nonmissing.

†

Mann-Whitney U test.

‡

Definition of WAS score is provided in Albert et al.¹

Details on these patients are provided in supplemental Table 1.

View Large

This Feature Is Available To Subscribers Only